Table of Contents for the Digital Edition of MD Conference Express ACC, 2011 MD Conference Express ACC, 2011 Contents What's New in ACCF/AHA Guidelines? Pharmacogenomic- or Pharmacodynamic- Tailored Antiplatelet Therapy: Is it Time for Personalized Medicine? PARTNER: Trial Results PARTNER: Cohort B Results One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study Results from the PLATINUM Trial 5-Year Results from the RAPS Trial Results from the RIVAL Trial EVEREST II Trial: Two-Year Outcomes Results from the TARGET Study EXCELLENT Trial 6- and 12-Month Results Results from the STICH Trial Myocardial Viability Does Not Predict Survival Benefit After CABG DES Reduce the Need for Repeat Revascularization Preventing Contrast-Induced Acute Kidney Injury: Results from the REMEDIAL Trial ll Devices CVD and Diabetes Heart Failure Myocardial Infarction Vitamin D and the Heart A Look into the Future: Elinogrel, Cangrelor, PAR Antagonists, and Aptamers MD Conference Express ACC, 2011 MD Conference Express ACC, 2011 - MD Conference Express ACC, 2011 (Page 1) MD Conference Express ACC, 2011 - MD Conference Express ACC, 2011 (Page 2) MD Conference Express ACC, 2011 - MD Conference Express ACC, 2011 (Page 3) MD Conference Express ACC, 2011 - MD Conference Express ACC, 2011 (Page 4) MD Conference Express ACC, 2011 - Contents (Page 5) MD Conference Express ACC, 2011 - What's New in ACCF/AHA Guidelines? (Page 6) MD Conference Express ACC, 2011 - What's New in ACCF/AHA Guidelines? (Page 7) MD Conference Express ACC, 2011 - What's New in ACCF/AHA Guidelines? (Page 8) MD Conference Express ACC, 2011 - Pharmacogenomic- or Pharmacodynamic- Tailored Antiplatelet Therapy: Is it Time for Personalized Medicine? (Page 9) MD Conference Express ACC, 2011 - Pharmacogenomic- or Pharmacodynamic- Tailored Antiplatelet Therapy: Is it Time for Personalized Medicine? (Page 10) MD Conference Express ACC, 2011 - Pharmacogenomic- or Pharmacodynamic- Tailored Antiplatelet Therapy: Is it Time for Personalized Medicine? (Page 11) MD Conference Express ACC, 2011 - PARTNER: Trial Results (Page 12) MD Conference Express ACC, 2011 - PARTNER: Cohort B Results (Page 13) MD Conference Express ACC, 2011 - One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study (Page 14) MD Conference Express ACC, 2011 - 5-Year Results from the RAPS Trial (Page 15) MD Conference Express ACC, 2011 - Results from the RIVAL Trial (Page 16) MD Conference Express ACC, 2011 - EVEREST II Trial: Two-Year Outcomes (Page 17) MD Conference Express ACC, 2011 - Results from the TARGET Study (Page 18) MD Conference Express ACC, 2011 - EXCELLENT Trial 6- and 12-Month Results (Page 19) MD Conference Express ACC, 2011 - Results from the STICH Trial (Page 20) MD Conference Express ACC, 2011 - Myocardial Viability Does Not Predict Survival Benefit After CABG (Page 21) MD Conference Express ACC, 2011 - Preventing Contrast-Induced Acute Kidney Injury: Results from the REMEDIAL Trial ll (Page 22) MD Conference Express ACC, 2011 - Preventing Contrast-Induced Acute Kidney Injury: Results from the REMEDIAL Trial ll (Page 23) MD Conference Express ACC, 2011 - Devices (Page 24) MD Conference Express ACC, 2011 - Devices (Page 25) MD Conference Express ACC, 2011 - CVD and Diabetes (Page 26) MD Conference Express ACC, 2011 - CVD and Diabetes (Page 27) MD Conference Express ACC, 2011 - Heart Failure (Page 28) MD Conference Express ACC, 2011 - Heart Failure (Page 29) MD Conference Express ACC, 2011 - Myocardial Infarction (Page 30) MD Conference Express ACC, 2011 - Myocardial Infarction (Page 31) MD Conference Express ACC, 2011 - Vitamin D and the Heart (Page 32) MD Conference Express ACC, 2011 - A Look into the Future: Elinogrel, Cangrelor, PAR Antagonists, and Aptamers (Page 33) MD Conference Express ACC, 2011 - A Look into the Future: Elinogrel, Cangrelor, PAR Antagonists, and Aptamers (Page 34) MD Conference Express ACC, 2011 - A Look into the Future: Elinogrel, Cangrelor, PAR Antagonists, and Aptamers (Page 35) MD Conference Express ACC, 2011 - A Look into the Future: Elinogrel, Cangrelor, PAR Antagonists, and Aptamers (Page 36) http://www.nxtbook.com/nxtbooks/md_conference_express/acc2011 http://www.nxtbookMEDIA.com
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.